$LAURUSLABS

$LAURUSLABS Laurus Labs is a leading pharmaceutical and biotech company with strong capabilities in Active Pharmaceutical Ingredients (APIs), Contract Development & Manufacturing (CDMO), formulations, and biotechnology products. The company is a key supplier to global markets, particularly in anti-retroviral, oncology, and specialty therapeutic segments. FY25 revenue was approximately ₹5,500–5,700 crore, with EBITDA exceeding ₹1,000 crore and PAT recovering as demand improved across key business verticals. Its diversified business model and strong R&D focus support long-term growth. Latest News: Laurus Labs has been expanding its CDMO and biologics businesses, securing new customer projects and increasing manufacturing capacities to meet growing global demand. The company is also benefiting from the China+1 sourcing trend and rising outsourcing by global pharmaceutical companies. With a strong order pipeline, increasing contribution from high-margin CDMO operations, and continued investments in innovation and capacity expansion, Laurus Labs is well-positioned to deliver sustainable growth over the long term, though regulatory and pricing pressures remain key risks.